Hematological diseases: prototypical conditions requiring the diagnostic and prognostic use of molecular data

Seminars in Diagnostic Pathology
Kaaren K Reichard, Curtis A Hanson

Abstract

The field of diagnostic hematopathology is dynamic and evolving given the ongoing accumulation of molecular information and demand for integration of this information into routine clinical practice. In light of this molecular revolution, the appropriate and effective utilization of molecular studies by clinicians/pathologists is of paramount importance to the current diagnosis, prognosis, and monitoring of nearly all hematologic diseases. In the routine workup of certain hematologic neoplasms, it is more pertinent and practical to understand the purpose of these analyses and how to generally apply them to particular diseases rather than trying to remember a likely outdated list of genes. We will see advances in the treatment of hematologic malignancies as drug development catches up to our molecular understanding of diseases.

References

Jan 3, 2001·The New England Journal of Medicine·H DöhnerP Lichter
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
May 3, 2008·The New England Journal of Medicine·Richard F SchlenkUNKNOWN German-Austrian Acute Myeloid Leukemia Study Group
Jun 2, 2009·Nature Genetics·Saskia M C LangemeijerJoop H Jansen
Aug 12, 2009·Blood·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Sep 11, 2009·The New England Journal of Medicine·Ayalew TefferiRoss Levine
Oct 3, 2009·Leukemia·R FonsecaUNKNOWN International Myeloma Working Group
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Katharina WagnerJürgen Krauter
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Jun 15, 2010·Leukemia Research·Rosangela Pinheiro Gonçalves MachadoRonald Feitosa Pinheiro
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander KohlmannTorsten Haferlach
Aug 21, 2010·Leukemia·H MakishimaJ P Maciejewski
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciHartmut Döhner
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Klaus H MetzelerClara D Bloomfield
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Verena I GaidzikKonstanze Döhner
Mar 19, 2011·Leukemia·M J WalterT A Graubert
Apr 27, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin JäderstenGhulam J Mufti
Jun 15, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Felicitas TholMichael Heuser
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie SchanzDetlef Haase
Mar 16, 2012·The New England Journal of Medicine·Jay P PatelRoss L Levine
Mar 21, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Verena I GaidzikKonstanze Döhner
Mar 23, 2012·Journal of Hematology & Oncology·Véronique Gelsi-BoyerDaniel Birnbaum

❮ Previous
Next ❯

Citations

Jan 24, 2019·Archives of Pathology & Laboratory Medicine·Lauren N PearsonMary E Tang

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

American Journal of Clinical Pathology
D S Harrington
Clinical Laboratory Science : Journal of the American Society for Medical Technology
Susan J Leclair, Bernadette F Rodak
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
C SambadeC Sundström
© 2021 Meta ULC. All rights reserved